CN110831596B - 作为蛋白激酶抑制剂的氨基噻唑化合物 - Google Patents

作为蛋白激酶抑制剂的氨基噻唑化合物 Download PDF

Info

Publication number
CN110831596B
CN110831596B CN201880039827.XA CN201880039827A CN110831596B CN 110831596 B CN110831596 B CN 110831596B CN 201880039827 A CN201880039827 A CN 201880039827A CN 110831596 B CN110831596 B CN 110831596B
Authority
CN
China
Prior art keywords
compound
cancer
compounds
alkyl
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880039827.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110831596A (zh
Inventor
石全
蒋维棠
蔡慧珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiwan Institute Of Health
Original Assignee
Taiwan Institute Of Health
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Institute Of Health, National Health Research Institutes filed Critical Taiwan Institute Of Health
Publication of CN110831596A publication Critical patent/CN110831596A/zh
Application granted granted Critical
Publication of CN110831596B publication Critical patent/CN110831596B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880039827.XA 2017-06-13 2018-06-13 作为蛋白激酶抑制剂的氨基噻唑化合物 Active CN110831596B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
US62/518,855 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN110831596A CN110831596A (zh) 2020-02-21
CN110831596B true CN110831596B (zh) 2025-01-24

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880039827.XA Active CN110831596B (zh) 2017-06-13 2018-06-13 作为蛋白激酶抑制剂的氨基噻唑化合物

Country Status (13)

Country Link
US (1) US10300061B2 (cg-RX-API-DMAC7.html)
EP (1) EP3638237B1 (cg-RX-API-DMAC7.html)
JP (1) JP6979595B2 (cg-RX-API-DMAC7.html)
KR (1) KR102372288B1 (cg-RX-API-DMAC7.html)
CN (1) CN110831596B (cg-RX-API-DMAC7.html)
AU (1) AU2018284249B2 (cg-RX-API-DMAC7.html)
CA (1) CA3064081C (cg-RX-API-DMAC7.html)
ES (1) ES2949616T3 (cg-RX-API-DMAC7.html)
MX (1) MX393992B (cg-RX-API-DMAC7.html)
MY (1) MY201291A (cg-RX-API-DMAC7.html)
TW (1) TWI667236B (cg-RX-API-DMAC7.html)
WO (1) WO2018231910A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202000107B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
KR20220103744A (ko) * 2019-11-14 2022-07-22 에이2에이 파마수티칼스, 잉크. 항암제로서 tacc3을 표적으로 하는 이속사졸 유도체
JP7691991B2 (ja) * 2020-03-06 2025-06-12 ナショナル・ヘルス・リサーチ・インスティテューツ ピリミジン化合物及びその薬学的使用
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
CA3246244A1 (en) 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. CANCER COMPOSITIONS AND TREATMENT METHODS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558609A4 (en) 2002-10-30 2008-05-28 Merck & Co Inc KINASE INHIBITORS
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
JP2008543754A (ja) * 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
GB0610909D0 (en) * 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
WO2008033746A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
ES2573831T3 (es) * 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors;Cinzia Maria Francini et al;《Chem med Chem》;20151231;第10卷;第2027-2041页,尤其是第2029页表1 *

Also Published As

Publication number Publication date
RU2019137573A3 (cg-RX-API-DMAC7.html) 2021-07-23
EP3638237B1 (en) 2023-04-19
EP3638237A4 (en) 2021-01-13
BR112019026577A8 (pt) 2023-04-11
US10300061B2 (en) 2019-05-28
CA3064081A1 (en) 2018-12-20
MY201291A (en) 2024-02-15
TWI667236B (zh) 2019-08-01
ES2949616T3 (es) 2023-10-02
JP2020523348A (ja) 2020-08-06
AU2018284249B2 (en) 2021-06-24
MX2019014845A (es) 2020-08-06
CA3064081C (en) 2023-03-21
KR20200014350A (ko) 2020-02-10
WO2018231910A1 (en) 2018-12-20
MX393992B (es) 2025-03-24
CN110831596A (zh) 2020-02-21
KR102372288B1 (ko) 2022-03-08
EP3638237A1 (en) 2020-04-22
ZA202000107B (en) 2020-12-23
US20180353509A1 (en) 2018-12-13
NZ759327A (en) 2021-08-27
RU2019137573A (ru) 2021-05-24
AU2018284249A1 (en) 2019-12-12
TW201906836A (zh) 2019-02-16
BR112019026577A2 (pt) 2020-06-23
JP6979595B2 (ja) 2021-12-15

Similar Documents

Publication Publication Date Title
TWI667236B (zh) 作為蛋白激酶抑制劑的胺基噻唑化合物
EP2498607B1 (en) Kinase inhibitors
AU2014351571B2 (en) 1 -(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer
JP7240784B2 (ja) 8,9-ジヒドロイミダゾール[1,2-a]ピリミド[5,4-e]ピリミジン-5(6H)-ケトン類化合物
AU2018222073B2 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
JP7568641B2 (ja) 治療的使用のためのキナーゼ阻害剤としての複素環式化合物
JP6101341B2 (ja) 置換ピリドピリミジン化合物およびflt3阻害剤としてのこれらの使用
CN106795144B (zh) 用于调节egfr突变体激酶活性的化合物和组合物
TWI707855B (zh) 咪唑并嗒類化合物及其用途
CA2992981C (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
KR102256497B1 (ko) 포스파티딜이노시톨 3-키나아제 억제제로서의 퀴놀린 유사체
JP2022547294A (ja) キナーゼ阻害剤としての3,5-ジ置換ピラゾール化合物およびその応用
TWI565698B (zh) 喹啉化合物,其製造方法及用途
CN106467540B (zh) 蝶啶酮衍生物作为flt3抑制剂的应用
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
RU2772645C2 (ru) Аминотиазольные соединения в качестве ингибиторов протеинкиназ
HK40017909B (en) Aminothiazole compounds as protein kinase inhibitors
HK40017909A (en) Aminothiazole compounds as protein kinase inhibitors
TWI750905B (zh) 噻唑化合物作為蛋白質激酶抑制劑
NZ759327B2 (en) Aminothiazole compounds as protein kinase inhibitors
BR112019026577B1 (pt) Compostos aminotiazol, composição farmacêutica e uso como inibidores de proteína quinase e no tratamento de câncer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017909

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210907

Address after: Miaoli County, Taiwan, China

Applicant after: Taiwan Institute of health

Address before: Miaoli County, Taiwan, China

Applicant before: NATIONAL HEALTH RESEARCH INSTITUTES

Applicant before: Shi Quan

GR01 Patent grant
GR01 Patent grant